EDAPEDAP TMS SA

Nasdaq edap-tms.com


$ 3.22 $ 0.01 (0.31 %)    

Wednesday, 11-Sep-2024 15:59:34 EDT
QQQ $ 469.71 $ 1.08 (0.23 %)
DIA $ 409.08 $ -0.38 (-0.09 %)
SPY $ 555.06 $ 0.07 (0.01 %)
TLT $ 99.94 $ -0.43 (-0.43 %)
GLD $ 235.95 $ 1.31 (0.56 %)
$ 3.23
-- x --
-- x --
-- - --
$ 2.71 - $ 8.50
15,391
na
119.85M
$ 0.77
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-edap-tms-maintains-19-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Edap TMS (NASDAQ:EDAP) with a Buy and maintains $19 price ...

 edap-tms-q2-2024-gaap-eps-018-misses-012-estimate-sales-16970m-beat-15695m-estimate

Edap TMS (NASDAQ:EDAP) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.12) by...

 hc-wainwright--co-reiterates-buy-on-edap-tms-maintains-19-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Edap TMS (NASDAQ:EDAP) with a Buy and maintains $19 price ...

 edap-reports-interim-results-from-phase-3-study-evaluating-robotic-hifu-for-deep-infiltrating-endometriosis

Robotic HIFU therapy continues to maintain an excellent safety profile, confirming positive safety data from prior Phase 1 and ...

 hc-wainwright--co-reiterates-buy-on-edap-tms-maintains-19-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Edap TMS (NASDAQ:EDAP) with a Buy and maintains $19 price ...

 edap-announces-final-results-from-the-hifi-study-comparing-outcomes-of-focal-one-hifu-versus-radical-prostatectomy-during-plenary-session-at-the-119th-american-urological-association-annual-meeting

Final results demonstrate a significantly higher salvage treatment free survival rate (STFS) at 30 months of 89.6% in the HIFU-...

 edap-tms-sa-files-for-mixed-shelf-of-up-to-125m

- SEC Filing

 hc-wainwright--co-maintains-buy-on-edap-tms-raises-price-target-to-19

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Edap TMS (NASDAQ:EDAP) with a Buy and raises the price targ...

 edap-tms-q4-eps-015-misses-005-estimate-sales-2130m-beat-1966m-estimate

Edap TMS (NASDAQ:EDAP) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.05) by...

 earnings-scheduled-for-march-27-2024

Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on rev...

 earnings-outlook-for-edap-tms
Earnings Outlook For Edap TMS
03/26/2024 15:01:15

 edap-announces-fda-breakthrough-device-designation-for-focal-one-in-the-treatment-of-deep-infiltrating-rectal-endometriosis

EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, announced today that its Focal One platform has...

 edap-announces-completion-of-enrollment-in-phase-3-study-evaluating-focal-one-hifu-therapy-for-deep-infiltrating-rectal-endometriosis

60 Patients Completed Enrollment in Under 9 MonthsStudy Results Expected in the Second Half of 2024

 edap-announces-preliminary-q4-record-focal-one-system-sales-and-placements-company-reports-preliminary-placement-results-of-twelve-focal-one-systems-inclusive-of-ten-capital-sales

Company reports preliminary placement results of twelve Focal One Systems, inclusive of ten capital salesLYON, France, January ...

 edap-announces-positive-opinion-for-reimbursement-from-the-french-national-authority-for-health-for-hifu-treatment-of-prostate-cancer

EDAP TMS SA (NASDAQ:EDAP), ("EDAP"), the global leader in robotic energy-based therapies, today announced that the Fren...

 piper-sandler-maintains-overweight-on-edap-tms-lowers-price-target-to-9-report-released-on-9th-nov-2023

Piper Sandler analyst Jason Bednar maintains Edap TMS (NASDAQ:EDAP) with a Overweight and lowers the price target from $14 t...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION